Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

62Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies. © 2005 Cancer Research.

Cite

CITATION STYLE

APA

Bartlett, J. B., Tozer, A., Stirling, D., & Zeldis, J. B. (2005, September 19). Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602774

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free